AustralieFrV1, PascalFrancis, Checkpoint, bibRecord, 006523

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer

Identifieur interne : 006523 ( PascalFrancis/Checkpoint ); précédent : 006522; suivant : 006524

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer

Auteurs : M. Friedlander [Australie] ; M. J. Millward [Australie] ; D. Bell [Australie] ; R. Bugat [France] ; P. Harnett [Australie] ; J. A. Moreno [Espagne] ; L. Campbell [France] ; C. Varette [Australie] ; V. Ripoche [France] ; L. Kayitalire [France]

Source :

Annals of oncology [ 0923-7534 ] ; 1998.

RBID : Pascal:99-0170681

Descripteurs français

Pascal (Inist)
- Cisplatine, Gemcitabine, Anticancéreux, Chimiothérapie, Traitement rattrapage, Tumeur maligne, Ovaire, Stade avancé, Homme, Femelle, Essai clinique phase II, Récidive, Toxicité, Voie intraveineuse, Platine II Complexe, Pyrimidine nucléoside, Fluor Composé organique.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Advanced stage, Antineoplastic agent, Chemotherapy, Cisplatin, Female, Fluorine Organic compounds, Gemcitabine, Human, Intravenous administration, Malignant tumor, Ovary, Phase II trial, Platinum II Complexes, Pyrimidine nucleoside, Relapse, Salvage treatment, Toxicity.

Abstract

Background. Most patients with advanced ovarian cancer will relapse following platinum-based combination chemotherapy and be considered for second-line treatment. Gemcitabine, a nucleoside analogue, is active against a range of solid tumors. This phase II study investigated the activity of single-agent gemcitabine in patients with recurrent ovarian cancer. Patients and methods: Thirty-eight patients with FIGO stage 111 (34%) or IV (64%) ovarian cancer who were previously treated with platinum-containing regimens were enrolled. Patients received 1200 mg/m² gemcitabine on days 1, 8 and 15 of a 28-day cycle. Results: Patients completed an average of 3.6 cycles. Two complete and three partial responses were seen in 36 evaluable patients, for an overall response rate of 13.9% (95% CI: 4.7%-29.5%). The median survival time was 6.7 months. Toxicities were generally mild. The most common were grade 3-4 neutropenia and grade 3 leukopenia reported in 23.7% and 10.5% of patients, respectively. One patient had grade 4 pulmonary toxicity. Conclusion: Single-agent gemcitabine is active and well tolerated in patients with recurrent ovarian cancer.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 006418
to stream PascalFrancis, to step Curation: 006C36

Links to Exploration step

Pascal:99-0170681

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer</title>
<author><name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M." last="Friedlander">M. Friedlander</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Prince of Wales Hospital</s1>
<s2>Randwick</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Prince of Wales Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Millward, M J" sort="Millward, M J" uniqKey="Millward M" first="M. J." last="Millward">M. J. Millward</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Peter Maccallum Cancer Institute</s1>
<s2>East Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Peter Maccallum Cancer Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bell, D" sort="Bell, D" uniqKey="Bell D" first="D." last="Bell">D. Bell</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Royal North Shore Hospital</s1>
<s2>St. Leonards</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Royal North Shore Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bugat, R" sort="Bugat, R" uniqKey="Bugat R" first="R." last="Bugat">R. Bugat</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Centre Claudius Régaud</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Harnett, P" sort="Harnett, P" uniqKey="Harnett P" first="P." last="Harnett">P. Harnett</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Westmead Hospital</s1>
<s2>Westmead</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Westmead Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moreno, J A" sort="Moreno, J A" uniqKey="Moreno J" first="J. A." last="Moreno">J. A. Moreno</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Hospital Universitatio Virgen del Rocio</s1>
<s2>Sevilla</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Hospital Universitatio Virgen del Rocio</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Campbell, L" sort="Campbell, L" uniqKey="Campbell L" first="L." last="Campbell">L. Campbell</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Hôpital Saint-Antoine</s1>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Hôpital Saint-Antoine</wicri:noRegion>
<wicri:noRegion>Hôpital Saint-Antoine</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Varette, C" sort="Varette, C" uniqKey="Varette C" first="C." last="Varette">C. Varette</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Lilly Australia</s1>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Lilly Australia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ripoche, V" sort="Ripoche, V" uniqKey="Ripoche V" first="V." last="Ripoche">V. Ripoche</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Lilly France</s1>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Lilly France</wicri:noRegion>
<wicri:noRegion>Lilly France</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kayitalire, L" sort="Kayitalire, L" uniqKey="Kayitalire L" first="L." last="Kayitalire">L. Kayitalire</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Lilly France</s1>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Lilly France</wicri:noRegion>
<wicri:noRegion>Lilly France</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0170681</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 99-0170681 INIST</idno>
<idno type="RBID">Pascal:99-0170681</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">006418</idno>
<idno type="wicri:Area/PascalFrancis/Curation">006C36</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">006523</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">006523</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer</title>
<author><name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M." last="Friedlander">M. Friedlander</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Prince of Wales Hospital</s1>
<s2>Randwick</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Prince of Wales Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Millward, M J" sort="Millward, M J" uniqKey="Millward M" first="M. J." last="Millward">M. J. Millward</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Peter Maccallum Cancer Institute</s1>
<s2>East Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Peter Maccallum Cancer Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bell, D" sort="Bell, D" uniqKey="Bell D" first="D." last="Bell">D. Bell</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Royal North Shore Hospital</s1>
<s2>St. Leonards</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Royal North Shore Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bugat, R" sort="Bugat, R" uniqKey="Bugat R" first="R." last="Bugat">R. Bugat</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Centre Claudius Régaud</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Harnett, P" sort="Harnett, P" uniqKey="Harnett P" first="P." last="Harnett">P. Harnett</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Westmead Hospital</s1>
<s2>Westmead</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Westmead Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moreno, J A" sort="Moreno, J A" uniqKey="Moreno J" first="J. A." last="Moreno">J. A. Moreno</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Hospital Universitatio Virgen del Rocio</s1>
<s2>Sevilla</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
<wicri:noRegion>Hospital Universitatio Virgen del Rocio</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Campbell, L" sort="Campbell, L" uniqKey="Campbell L" first="L." last="Campbell">L. Campbell</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Hôpital Saint-Antoine</s1>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Hôpital Saint-Antoine</wicri:noRegion>
<wicri:noRegion>Hôpital Saint-Antoine</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Varette, C" sort="Varette, C" uniqKey="Varette C" first="C." last="Varette">C. Varette</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Lilly Australia</s1>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Lilly Australia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ripoche, V" sort="Ripoche, V" uniqKey="Ripoche V" first="V." last="Ripoche">V. Ripoche</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Lilly France</s1>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Lilly France</wicri:noRegion>
<wicri:noRegion>Lilly France</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kayitalire, L" sort="Kayitalire, L" uniqKey="Kayitalire L" first="L." last="Kayitalire">L. Kayitalire</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Lilly France</s1>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Lilly France</wicri:noRegion>
<wicri:noRegion>Lilly France</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
<imprint><date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of oncology</title>
<title level="j" type="abbreviated">Ann. oncol.</title>
<idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Antineoplastic agent</term>
<term>Chemotherapy</term>
<term>Cisplatin</term>
<term>Female</term>
<term>Fluorine Organic compounds</term>
<term>Gemcitabine</term>
<term>Human</term>
<term>Intravenous administration</term>
<term>Malignant tumor</term>
<term>Ovary</term>
<term>Phase II trial</term>
<term>Platinum II Complexes</term>
<term>Pyrimidine nucleoside</term>
<term>Relapse</term>
<term>Salvage treatment</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cisplatine</term>
<term>Gemcitabine</term>
<term>Anticancéreux</term>
<term>Chimiothérapie</term>
<term>Traitement rattrapage</term>
<term>Tumeur maligne</term>
<term>Ovaire</term>
<term>Stade avancé</term>
<term>Homme</term>
<term>Femelle</term>
<term>Essai clinique phase II</term>
<term>Récidive</term>
<term>Toxicité</term>
<term>Voie intraveineuse</term>
<term>Platine II Complexe</term>
<term>Pyrimidine nucléoside</term>
<term>Fluor Composé organique</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background. Most patients with advanced ovarian cancer will relapse following platinum-based combination chemotherapy and be considered for second-line treatment. Gemcitabine, a nucleoside analogue, is active against a range of solid tumors. This phase II study investigated the activity of single-agent gemcitabine in patients with recurrent ovarian cancer. Patients and methods: Thirty-eight patients with FIGO stage 111 (34%) or IV (64%) ovarian cancer who were previously treated with platinum-containing regimens were enrolled. Patients received 1200 mg/m<sup>2</sup>
 gemcitabine on days 1, 8 and 15 of a 28-day cycle. Results: Patients completed an average of 3.6 cycles. Two complete and three partial responses were seen in 36 evaluable patients, for an overall response rate of 13.9% (95% CI: 4.7%-29.5%). The median survival time was 6.7 months. Toxicities were generally mild. The most common were grade 3-4 neutropenia and grade 3 leukopenia reported in 23.7% and 10.5% of patients, respectively. One patient had grade 4 pulmonary toxicity. Conclusion: Single-agent gemcitabine is active and well tolerated in patients with recurrent ovarian cancer.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0923-7534</s0>
</fA01>
<fA03 i2="1"><s0>Ann. oncol.</s0>
</fA03>
<fA05><s2>9</s2>
</fA05>
<fA06><s2>12</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>FRIEDLANDER (M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MILLWARD (M. J.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BELL (D.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BUGAT (R.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HARNETT (P.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MORENO (J. A.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CAMPBELL (L.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>VARETTE (C.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>RIPOCHE (V.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>KAYITALIRE (L.)</s1>
</fA11>
<fA14 i1="01"><s1>Prince of Wales Hospital</s1>
<s2>Randwick</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Peter Maccallum Cancer Institute</s1>
<s2>East Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Royal North Shore Hospital</s1>
<s2>St. Leonards</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Centre Claudius Régaud</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Westmead Hospital</s1>
<s2>Westmead</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Hospital Universitatio Virgen del Rocio</s1>
<s2>Sevilla</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Hôpital Saint-Antoine</s1>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Lilly Australia</s1>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Lilly France</s1>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>1343-1345</s1>
</fA20>
<fA21><s1>1998</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22429</s2>
<s5>354000074245920150</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>15 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0170681</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of oncology</s0>
</fA64>
<fA66 i1="01"><s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background. Most patients with advanced ovarian cancer will relapse following platinum-based combination chemotherapy and be considered for second-line treatment. Gemcitabine, a nucleoside analogue, is active against a range of solid tumors. This phase II study investigated the activity of single-agent gemcitabine in patients with recurrent ovarian cancer. Patients and methods: Thirty-eight patients with FIGO stage 111 (34%) or IV (64%) ovarian cancer who were previously treated with platinum-containing regimens were enrolled. Patients received 1200 mg/m<sup>2</sup>
 gemcitabine on days 1, 8 and 15 of a 28-day cycle. Results: Patients completed an average of 3.6 cycles. Two complete and three partial responses were seen in 36 evaluable patients, for an overall response rate of 13.9% (95% CI: 4.7%-29.5%). The median survival time was 6.7 months. Toxicities were generally mild. The most common were grade 3-4 neutropenia and grade 3 leukopenia reported in 23.7% and 10.5% of patients, respectively. One patient had grade 4 pulmonary toxicity. Conclusion: Single-agent gemcitabine is active and well tolerated in patients with recurrent ovarian cancer.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02R02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Cisplatine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Cisplatin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Cisplatino</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Gemcitabine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Gemcitabine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Gemcitabina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Traitement rattrapage</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Salvage treatment</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tratamiento salvamento</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Ovaire</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Ovary</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Ovario</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Stade avancé</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Advanced stage</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estadio avanzado</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Femelle</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Female</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hembra</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Essai clinique phase II</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Phase II trial</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Ensayo clínico fase II</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Récidive</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Relapse</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Recaida</s0>
<s5>20</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>21</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>21</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>21</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Voie intraveineuse</s0>
<s5>22</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Intravenous administration</s0>
<s5>22</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Vía intravenosa</s0>
<s5>22</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Platine II Complexe</s0>
<s2>NC</s2>
<s2>NA</s2>
<s5>25</s5>
<s6>Platine «II» Complexe</s6>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Platinum II Complexes</s0>
<s2>NC</s2>
<s2>NA</s2>
<s5>25</s5>
<s6>Platinum «II» Complexes</s6>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Platino II Complejo</s0>
<s2>NC</s2>
<s2>NA</s2>
<s5>25</s5>
<s6>Platino «II» Complejo</s6>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Pyrimidine nucléoside</s0>
<s5>27</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Pyrimidine nucleoside</s0>
<s5>27</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Pirimidina nucleósido</s0>
<s5>27</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Fluor Composé organique</s0>
<s2>NC</s2>
<s2>FX</s2>
<s2>NA</s2>
<s5>28</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Fluorine Organic compounds</s0>
<s2>NC</s2>
<s2>FX</s2>
<s2>NA</s2>
<s5>28</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Fluor Compuesto orgánico</s0>
<s2>NC</s2>
<s2>FX</s2>
<s2>NA</s2>
<s5>28</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil génital femelle pathologie</s0>
<s5>69</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Female genital diseases</s0>
<s5>69</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato genital hembra patología</s0>
<s5>69</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Ovaire pathologie</s0>
<s5>70</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Ovarian diseases</s0>
<s5>70</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Ovario patología</s0>
<s5>70</s5>
</fC07>
<fN21><s1>102</s1>
</fN21>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Australie</li>
<li>Espagne</li>
<li>France</li>
</country>
<region><li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
</region>
<settlement><li>Toulouse</li>
</settlement>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M." last="Friedlander">M. Friedlander</name>
</noRegion>
<name sortKey="Bell, D" sort="Bell, D" uniqKey="Bell D" first="D." last="Bell">D. Bell</name>
<name sortKey="Harnett, P" sort="Harnett, P" uniqKey="Harnett P" first="P." last="Harnett">P. Harnett</name>
<name sortKey="Millward, M J" sort="Millward, M J" uniqKey="Millward M" first="M. J." last="Millward">M. J. Millward</name>
<name sortKey="Varette, C" sort="Varette, C" uniqKey="Varette C" first="C." last="Varette">C. Varette</name>
</country>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Bugat, R" sort="Bugat, R" uniqKey="Bugat R" first="R." last="Bugat">R. Bugat</name>
</region>
<name sortKey="Campbell, L" sort="Campbell, L" uniqKey="Campbell L" first="L." last="Campbell">L. Campbell</name>
<name sortKey="Kayitalire, L" sort="Kayitalire, L" uniqKey="Kayitalire L" first="L." last="Kayitalire">L. Kayitalire</name>
<name sortKey="Ripoche, V" sort="Ripoche, V" uniqKey="Ripoche V" first="V." last="Ripoche">V. Ripoche</name>
</country>
<country name="Espagne"><noRegion><name sortKey="Moreno, J A" sort="Moreno, J A" uniqKey="Moreno J" first="J. A." last="Moreno">J. A. Moreno</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006523 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 006523 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:99-0170681
   |texte=   A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri